Published in J Exp Med on April 26, 2004
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol (2007) 7.86
The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest (2005) 3.83
Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest (2006) 2.58
Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol (2005) 2.53
Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol (2005) 2.49
Review series on helminths, immune modulation and the hygiene hypothesis: the broader implications of the hygiene hypothesis. Immunology (2009) 2.00
Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med (2005) 1.88
Microbes, immunoregulation, and the gut. Gut (2005) 1.80
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med (2005) 1.79
WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. J Exp Med (2007) 1.77
Suppressor T cells in human diseases. J Exp Med (2004) 1.73
FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One (2008) 1.73
Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A (2004) 1.69
Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2005) 1.67
Imbalance of regulatory T cells in human autoimmune diseases. Immunology (2006) 1.64
Autoimmune polyglandular syndrome Type 2: the tip of an iceberg? Clin Exp Immunol (2004) 1.61
Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest (2007) 1.56
Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol (2008) 1.44
Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood (2005) 1.39
Emergent autoimmunity in graft-versus-host disease. Blood (2005) 1.37
Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells. Immunology (2007) 1.35
Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol (2009) 1.30
Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis (2006) 1.17
Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol (2006) 1.16
Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology (2009) 1.14
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 1.12
Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology (2008) 1.09
Regulatory T cells in human autoimmune diseases. Springer Semin Immunopathol (2006) 1.07
Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation? Immunol Lett (2007) 1.05
Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis. Immunity (2010) 1.03
Tolerance, suppression and the fetal allograft. J Mol Med (Berl) (2004) 1.02
Regulating the immune system: the induction of regulatory T cells in the periphery. Arthritis Res Ther (2004) 0.98
Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One (2011) 0.95
Regulatory T-cell function is impaired in celiac disease. Dig Dis Sci (2008) 0.93
Can mesenchymal stem cells reverse chronic stress-induced impairment of lung healing following traumatic injury? J Trauma Acute Care Surg (2015) 0.92
Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant (2013) 0.90
CD4⁺ CD45RA⁻ FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin Exp Immunol (2013) 0.90
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood (2011) 0.88
Forkhead transcription factors in chronic inflammation. Int J Biochem Cell Biol (2009) 0.87
Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus. Int J Mol Sci (2015) 0.86
Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. Endocr Relat Cancer (2014) 0.85
Interleukin-4 supports interleukin-12-induced proliferation and interferon-gamma secretion in human activated lymphoblasts and T helper type 1 cells. Immunology (2006) 0.84
The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients. Clin Immunol (2009) 0.84
T cells stimulated in vitro have a suppressive function but do not contain only regulatory T cells. Clin Exp Immunol (2007) 0.83
Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases. Mediterr J Hematol Infect Dis (2012) 0.81
Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res (2014) 0.80
Efficient expansion of cryopreserved CD4(+)CD25(+)CD127(lo/-) cells in Type 1 diabetes. Results Immunol (2011) 0.80
Transforming growth factor beta 1 production by CD4+ CD25+ regulatory T cells in peripheral blood mononuclear cells from healthy subjects stimulated with Leishmania guyanensis. Infect Immun (2005) 0.80
Regulatory T cells in renal disease. Int J Clin Exp Med (2008) 0.79
IL-2 suppression of IL-12p70 by a recombinant HSV-1 expressing IL-2 induces T-cell auto-reactivity and CNS demyelination. PLoS One (2011) 0.79
Insights into type 1 diabetes from the autoimmune polyendocrine syndromes. Curr Opin Endocrinol Diabetes Obes (2013) 0.79
Decreased Circulating T Regulatory Cells in Egyptian Patients with Nonsegmental Vitiligo: Correlation with Disease Activity. Dermatol Res Pract (2015) 0.78
Regulatory T cell kinetics in the peripheral blood of patients with Crohn's disease. Hum Immunol (2012) 0.77
The changing microbial environment and chronic inflammatory disorders. Allergy Asthma Clin Immunol (2008) 0.77
Vaccines against myasthenia gravis. Expert Opin Biol Ther (2005) 0.76
Regulatory T cells require renal antigen recognition through the TCR to protect against injury in nephritis. Int J Clin Exp Pathol (2013) 0.76
Impaired hapten sensitization in patients with autoimmune disease. Clin Exp Immunol (2011) 0.76
Exacerbation of spontaneous autoimmune nephritis following regulatory T cell depletion in B cell lymphoma 2-interacting mediator knock-out mice. Clin Exp Immunol (2017) 0.75
Systemic Activation of NRF2 Alleviates Lethal Autoimmune Inflammation in Scurfy Mice. Mol Cell Biol (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 15.27
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
Projection of an immunological self shadow within the thymus by the aire protein. Science (2002) 12.15
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol (2002) 9.18
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med (2001) 8.69
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 8.28
Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med (2001) 7.86
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev (2001) 7.60
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med (2001) 6.22
CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med (2003) 6.00
Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med (2003) 4.41
Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med (2002) 4.37
Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol (2001) 3.53
Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med (2002) 3.47
The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol (2002) 3.47
Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med (2002) 3.31
Early signaling defects in human T cells anergized by T cell presentation of autoantigen. J Exp Med (1992) 1.29
17. Immunologic endocrine disorders. J Allergy Clin Immunol (2003) 0.98
HLA-DQA1*0301-associated susceptibility for autoimmune polyglandular syndrome type II and III. Horm Metab Res (2003) 0.92
Autoimmune endocrine disease. Curr Opin Immunol (2002) 0.85
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med (2003) 3.42
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med (2008) 2.99
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.52
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum (2008) 2.27
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum (2009) 2.04
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol (2005) 1.81
Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. J Rheumatol (2010) 1.68
The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol (2005) 1.66
Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum (2005) 1.64
The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration (2004) 1.63
The evolution of human anti-double-stranded DNA autoantibodies. Proc Natl Acad Sci U S A (2005) 1.53
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Induction of CD4+ T-cell anergy and apoptosis by activated human B cells. Blood (2008) 1.49
Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum (2002) 1.46
Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum (2002) 1.39
Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum (2006) 1.36
Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther (2011) 1.35
Uveitis subtypes in a german interdisciplinary uveitis center--analysis of 1916 patients. J Rheumatol (2009) 1.34
15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol (2003) 1.32
Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum (2005) 1.31
Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev (2004) 1.25
Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther (2005) 1.22
Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis. Arthritis Rheum (2006) 1.17
Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. Arthritis Rheum (2007) 1.17
Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med (2004) 1.15
Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism (2011) 1.11
Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes. J Cell Sci (2010) 1.11
Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev (2005) 1.11
GATA-3 in human T cell helper type 2 development. J Exp Med (2004) 1.09
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther (2011) 1.09
Removal of dying cells and systemic lupus erythematosus. Mod Rheumatol (2005) 1.08
Involvement of phosphatidylserine, alphavbeta3, CD14, CD36, and complement C1q in the phagocytosis of primary necrotic lymphocytes by macrophages. Arthritis Rheum (2006) 1.07
Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol (2007) 1.06
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol (2008) 1.05
Cholera toxin binds to lipid rafts but has a limited specificity for ganglioside GM1. Immunol Cell Biol (2007) 1.04
Intestinal expression of TFF and related genes during postnatal development in a piglet probiotic trial. Cell Physiol Biochem (2009) 1.03
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord (2014) 1.03
Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol (2003) 1.01
Cooperation between C1q and DNase I in the clearance of necrotic cell-derived chromatin. Arthritis Rheum (2004) 1.01
Resistin levels in patients with obstructive sleep apnoea syndrome--the link to subclinical inflammation? Med Sci Monit (2004) 1.01
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol (2008) 1.00
ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun (2004) 1.00
B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun (2011) 0.99
Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. J Immunol (2004) 0.98
Tumor necrosis factor receptor-associated periodic syndrome characterized by a mutation affecting the cleavage site of the receptor: implications for pathogenesis. Arthritis Rheum (2003) 0.98
Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis. Arthritis Res Ther (2007) 0.97
Quality of life in chronic pancreatitis: a prospective trial comparing classical whipple procedure and duodenum-preserving pancreatic head resection. J Gastrointest Surg (2002) 0.97
Apoptosis and systemic lupus erythematosus. Rheum Dis Clin North Am (2004) 0.97
High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases. Isr Med Assoc J (2008) 0.96
Oral status in patients with early rheumatoid arthritis: a prospective, case-control study. Rheumatology (Oxford) (2013) 0.95
Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol (2002) 0.94
Characterization of monocyte-derived dendritic cells in recent-onset diabetes mellitus type 1. Clin Immunol (2002) 0.94
Antileukoproteinase: modulation of neutrophil function and therapeutic effects on anti-type II collagen antibody-induced arthritis. Arthritis Rheum (2004) 0.94
A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J Rheumatol (2003) 0.93
Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther (2012) 0.93
Leflunomide: a manageable safety profile. J Rheumatol Suppl (2004) 0.92
Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther (2011) 0.92
Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res (2006) 0.92
Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum (2006) 0.92
Sarcoidosis and the occurrence of malignant diseases. Rheumatol Int (2014) 0.92
Myocardial left ventricular dysfunction in patients with systemic lupus erythematosus: new insights from tissue Doppler and strain imaging. J Rheumatol (2009) 0.91
Defects in the disposal of dying cells lead to autoimmunity. Curr Rheumatol Rep (2004) 0.91
Outcome after duodenum-preserving pancreatic head resection is improved compared with classic Whipple procedure in the treatment of chronic pancreatitis. Surgery (2003) 0.90
Sensitive detection of plasma/serum DNA in patients with systemic lupus erythematosus. Autoimmunity (2007) 0.90
Selected pro-inflammatory factor transcripts in bovine endometrial epithelial cells are regulated during the oestrous cycle and elevated in case of subclinical or clinical endometritis. Reprod Fertil Dev (2010) 0.90
Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. Mol Pharmacol (2004) 0.90
Genetic and evolutionary analyses of the human bone morphogenetic protein receptor 2 (BMPR2) in the pathophysiology of obesity. PLoS One (2011) 0.90
Lectins detect changes of the glycosylation status of plasma membrane constituents during late apoptosis. Cytometry A (2006) 0.90
Prenatal testosterone excess alters Sertoli and germ cell number and testicular FSH receptor expression in rams. Am J Physiol Endocrinol Metab (2010) 0.90
A fast, simple and sensitive method for the detection and quantification of detergent-resistant membranes. J Immunol Methods (2002) 0.89
Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis. Rheumatology (Oxford) (2009) 0.88
The p38 mitogen-activated protein kinase regulates effector functions of primary human CD4 T cells. Eur J Immunol (2005) 0.88
During apoptosis HMGB1 is translocated into apoptotic cell-derived membranous vesicles. Autoimmunity (2013) 0.88
TLR9-activating DNA up-regulates ZAP70 via sustained PKB induction in IgM+ B cells. J Immunol (2008) 0.88
Tumor necrosis factor alpha in the bovine oviduct during the estrous cycle: messenger RNA expression and effect on secretion of prostaglandins, endothelin-1, and angiotensin II. Biol Reprod (2003) 0.88
Perspectives for TNF-alpha-targeting therapies. Arthritis Res (2002) 0.88
Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Ann N Y Acad Sci (2005) 0.88
Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. J Autoimmun (2012) 0.87
Induction of type I IFN is a physiological immune reaction to apoptotic cell-derived membrane microparticles. J Immunol (2012) 0.87
Controversies in COX-2 selective inhibition. J Rheumatol (2002) 0.86
Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus. Arthritis Rheumatol (2014) 0.86
CTLA-4 lacking the cytoplasmic domain costimulates IL-2 production in T-cell hybridomas. Immunol Cell Biol (2006) 0.86
Purified apoptotic bodies stimulate plasmacytoid dendritic cells to produce IFN-alpha. Autoimmunity (2007) 0.85
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody. Br J Haematol (2002) 0.85
RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed? Endocr Pract (2004) 0.85
The putative role of apoptosis-modified histones for the induction of autoimmunity in Systemic Lupus Erythematosus. Biochem Pharmacol (2003) 0.85